In previous phase 1-2 clinical trials involving older adults, a subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adjuvant system (called HZ/su) had a clinically acceptable safety profile and elicited a robust immune response.
Lal, H., Cunningham, A., Godeaux, O., Chlibek, R., Diez Domingo, J., Hwang, S., et al. (2015). Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. THE NEW ENGLAND JOURNAL OF MEDICINE, 372(22), 2087-2096 [10.1056/NEJMoa1501184].
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults
VOLPI, ANTONIO;
2015-05-01
Abstract
In previous phase 1-2 clinical trials involving older adults, a subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adjuvant system (called HZ/su) had a clinically acceptable safety profile and elicited a robust immune response.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.